Viral Vectors Summit 2026

Welcome to the Viral Vectors Summit 2026, where biotechnology and pharmaceutical leaders come together to explore the latest developments in advanced therapies shaping the future of the industry.

The biotherapeutics sector is rapidly advancing the development of viral carriers for gene therapies. Innovators in genetic and precision medicine are prioritizing next-generation oligonucleotide and protein therapies in vector design and production while maintaining safety, scalability, and efficacy.

Join us to connect with experts through sessions focused on manufacturing protocols, scalable production methods, and the integration of advanced genetic and protein therapies.

Future viral vector market forecasts and emerging economic trends

Analyze the projected rise in viral vector demand driven by gene therapies, and evaluate economic impacts, market scalability, and investment opportunities.

Emerging innovations shaping next-generation viral vector technologies

Learn about next-generation viral vector technologies that enhance gene delivery efficiency, specificity, and safety to improve overall gene therapy outcomes.

Patient-first safety strategies guiding viral vector dosing and redosing

Adopt patient-first frameworks to lower dose requirements, enable redosing, and manage immunogenicity, reducing risk and improving viral vector safety.

Developing next-generation precision gene therapies with targeted delivery

Explore technologies enabling precise gene editing and targeted vector delivery to specific tissues, improving efficacy and minimizing side effects.

Enhancing scalability with automated and efficient manufacturing processes

Unlock the potential of automation to improve analytics, scalability, and consistency in viral vector manufacturing while cutting costs and production time.

Overcoming regulatory challenges through clinical data harmonization

Discover strategies to overcome regulatory challenges through clinical data harmonization and alignment with global standards for viral vector technologies.

Expert Speakers

Past Attendees

hidden text

hidden text